PI3Kα-IN-4 是一种有效的，选择性和具有口服活性的 PI3Kα 抑制剂，IC₅₀ 值为 1.8 nM。PI3Kα-IN-4 具有抗肿瘤活性。

PI3Kα-IN-4 is a potent, selective and orally active inhibitor of PI3Kα, with an IC 50 of 1.8 nM. PI3Kα-IN-4 has antitumor activity.

Solid

PI3Kα 1.8 nM (IC50)

PI3Kα-IN-4 (compound 10) inhibits PI3Kα, β, δ, and γ, with IC50s of 1.8, 271.0, 13.9, and 13.8 nM, respectively in kinase assays.
PI3Kα-IN-4 inhibits PI3Kα, β, δ, and γ, with IC50s of 12.1,1393, 183, and >10000 nM, respectively in cell based assays. has not independently confirmed the accuracy of these methods. They are for reference only.

PI3Kα-IN-4 (compound 10) (30 mg/kg; p.o. once daily for 21 d) achieves the best efficacy, which could inhibit tumor growth by 73.0% in mice.
PI3Kα-IN-4 (15-40 mg/kg; p.o. once daily for 30 d) dose dependently suppresses tumor growth by 62.5% (15 mg/kg), 86.0% (30 mg/kg) and 90.7% (40 mg/kg), respectively in mice.
PI3Kα-IN-4 (15-40 mg/kg; p.o. once daily; 1-4 h) inhibits the phosphorylation of Akt in a dose- and time-dependent manner in vivo.
PI3Kα-IN-4 shows high C max (mouse 22167, rat 2327 nM) and good bioavailability (mouse 59.4%, rat 46.9%) following oral administration (mouse 10, rat 3 mg/kg).
PI3Kα-IN-4 shows t 1/2 (mouse 0.99, rat 1.22 h) and low plasma clearance (mouse 4.16, rat 5.28 mL/min/kg) following intravenous injection (mouse 1, rat 1 mg/kg).

Room temperature in continental US; may vary elsewhere.

Powder -20°C 3 years；4°C 2 years

[1]. Dong J, et, al. Discovery of 3-Quinazolin-4(3 H)-on-3-yl-2, N-dimethylpropanamides as Orally Active and Selective PI3Kα Inhibitors. ACS Med Chem Lett. 2020 Jun 10; 11(7): 1463-1469.

In Vitro: DMSO : 100 mg/mL (178.57 mM; Need ultrasonic)配制储备液